Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis
Authors:
- 9 February 2026
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (4) , 701-709
Abstract
Aims To evaluate whether continuing versus reducing metformin at imeglimin initiation is associated with 24-week changes in HbA1c and body weight in routine practice, and to describe 48-week outcomes. Methods Single-center retrospective study of adults with type 2 diabetes who started imeglimin 2000 mg/day (September 2022–August 2024). For the primary 24-week efficacy analysis, metformin users who tolerated and continued imeglimin through week 24 were classified as metformin continuation (no change) or metformin reduction (≥ 250 mg/day decrease, including discontinuation). The primary endpoint was 24-week ΔHbA1c. Associations were assessed with nonparametric tests and ANCOVA adjusting for age, sex, diabetes duration, and baseline HbA1c; sensitivity models additionally adjusted for baseline metformin dose and major concomitant glucose-lowering drug classes (SGLT2i, GLP-1RA, insulin, and sulfonylureas). Results Seventy metformin users were included (continuation n = 34; reduction n = 36). At 24 weeks, HbA1c decreased by − 0.6% versus − 0.2% (median difference − 0.5%, 95% CI − 0.6 to − 0.3), and body weight by − 1.2 kg versus − 0.4 kg (median difference − 0.9 kg). The absolute metformin dose reduction correlated with ΔHbA1c (Spearman ρ = 0.52). Metformin continuation remained associated with greater adjusted HbA1c reduction in sensitivity ANCOVA (adjusted difference − 0.57%, 95% CI − 0.88 to − 0.26; P = 0.0006). In a 48-week cohort (n = 65) continuing imeglimin, metformin dose reduction remained associated with ΔHbA1c in multivariable analysis. Conclusions Continuing metformin at imeglimin initiation was associated with greater improvements in HbA1c and body weight than dose reduction. Findings are associative and may reflect residual confounding.Keywords
This publication has 23 references indexed in Scilit:
- Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetesExpert Opinion on Pharmacotherapy, 2025
- A Multicenter, Retrospective Study to Evaluate the Effectiveness and Safety of Imeglimin in Patients with Type 2 Diabetes Mellitus in a Real-World Clinical Setting (INDI-TIMES Study)Diabetes Therapy, 2025
- Metformin: Diverse molecular mechanisms, gastrointestinal effects and overcoming intolerance in type 2 Diabetes Mellitus: A reviewMedicine, 2024
- Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in JapanDiabetes Research and Clinical Practice, 2024
- Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model miceMetabolism, 2024
- Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trialsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2023
- Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granulesScientific Reports, 2022
- The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cellsEndocrinology, Diabetes & Metabolism, 2021
- Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trialsDiabetes & Metabolism, 2020
- The mechanisms of action of metforminDiabetologia, 2017